{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T05:44:22Z","timestamp":1791870262227,"version":"4.3.4"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Polycystic ovary syndrome (PCOS) is a multifactorial endocrine disorder characterized by hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphology, frequently accompanied by insulin resistance, inflammation, and other metabolic disturbances. Chromogranin A (CgA), a glycoprotein secreted by neuroendocrine cells, has been linked to metabolic regulation and inflammatory processes, but its role in PCOS remains unexplored. This study aimed to evaluate serum CgA levels in women with PCOS and their association with metabolic, hormonal, and inflammatory parameters.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This case-control study included 75 women with PCOS, diagnosed according to the Rotterdam criteria, and 75 age-matched healthy controls, recruited between January and April 2021 at Istanbul Ayd\u0131n University Medical Park Florya Hospital. Serum CgA levels were measured using ELISA. Clinical parameters and biochemical markers, including glucose, insulin, HOMA-IR, lipid profile, sex hormones, SHBG, and hs-CRP, were assessed. Correlation, multivariate linear regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Mean serum CgA levels were significantly higher in the PCOS group than in controls (934.68 \u00b1 256.27 vs. 642.27 \u00b1 197.63 pg\/mL, p &amp;lt; 0.001). PCOS patients also had higher glucose, insulin, HOMA-IR, triglycerides, hs-CRP, LH, total testosterone, FAI, and DHEA-S, with lower HDL-C and SHBG (all p &amp;lt; 0.05). CgA correlated positively with BMI, glucose, insulin, HOMA-IR, and hs-CRP, and remained independently associated with BMI, HOMA-IR, and hs-CRP in multivariate analysis. In multivariable models, CgA remained independently associated with BMI, HOMA-IR, and hs-CRP. These findings suggest that CgA reflects the metabolic\u2013inflammatory milieu accompanying PCOS rather than indicating PCOS per se.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Elevated CgA levels in PCOS are independently associated with obesity, insulin resistance, and low-grade inflammation. CgA may serve as a novel biomarker for metabolic risk stratification in PCOS, warranting validation in larger, prospective studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2025.1682910","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T06:46:34Z","timestamp":1765953994000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Elevated serum chromogranin A levels are independently associated with metabolic and inflammatory disturbances in polycystic ovary syndrome"],"prefix":"10.3389","volume":"16","author":[{"given":"P\u0131nar","family":"Alarslan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Doruk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2018.24","article-title":"Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment","volume":"14","author":"Escobar-Morreale","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2019.116940","article-title":"Hyperandrogenemia and insulin resistance: the chief culprit of polycystic ovary syndrome","volume":"236","author":"Wang","year":"2019","journal-title":"Life Sci"},{"key":"B3","doi-asserted-by":"publisher","first-page":"67","DOI":"10.5114\/jogi.2018.79428","article-title":"The diagnosis and the reproductive and metabolic consequences of polycystic ovary syndrome","volume":"1","author":"AbuFaza","year":"2018","journal-title":"J Obstet Gynecol Investig"},{"key":"B4","doi-asserted-by":"publisher","first-page":"297","DOI":"10.34763\/devperiodmed.20182204.297300","article-title":"Chromogranin A: its known and possible roles in obstetrics and gynecology","volume":"22","author":"Niezgoda","year":"2018","journal-title":"Dev Period Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s00424-017-2030-y","article-title":"Circulating chromogranin A and its fragments as diagnostic and prognostic disease markers","volume":"470","author":"Corti","year":"2018","journal-title":"Pflugers Arch"},{"key":"B6","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/nyas.14249","article-title":"Chromogranin A and its fragments in cardiovascular, immunometabolic, and cancer regulation","volume":"1455","author":"Mahata","year":"2019","journal-title":"Ann N Y Acad Sci"},{"key":"B7","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.fertnstert.2003.10.004","article-title":"Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome","volume":"81","year":"2004","journal-title":"Fertil Steril"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.614679","article-title":"Impact of increased oxidative stress on cardiovascular diseases in women with polycystic ovary syndrome","volume":"12","author":"Duic\u0103","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa839","article-title":"Update on PCOS: consequences, challenges, and guiding treatment","volume":"106","author":"Hoeger","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/4092470","article-title":"Inflammatory markers in women with polycystic ovary syndrome","volume":"2020","author":"Rudnicka","year":"2020","journal-title":"BioMed Res Int"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.970733","article-title":"Characteristics and possible mechanisms of metabolic disorder in overweight women with polycystic ovary syndrome","volume":"13","author":"Yu","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-020-05838-8","article-title":"Association of metabolic and inflammatory markers with polycystic ovarian syndrome (PCOS): an update","volume":"303","author":"Abraham Gnanadass","year":"2021","journal-title":"Arch Gynecol Obstet"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1433612","article-title":"Genetically predicted serum metabolites mediate the association between inflammatory proteins and polycystic ovary syndrome: a Mendelian randomization study","volume":"11","author":"Jia","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"B14","doi-asserted-by":"publisher","first-page":"100937","DOI":"10.1016\/j.molmet.2020.01.001","article-title":"Metabolic dysfunction in polycystic ovary syndrome: pathogenic role of androgen excess and potential therapeutic strategies","volume":"35","author":"Sanchez-Garrido","year":"2020","journal-title":"Mol Metab"},{"key":"B15","first-page":"B5232","article-title":"Endocrine and metabolic characteristics in polycystic ovary syndrome","volume":"63","author":"Glintborg","year":"2015","journal-title":"Dan Med J"},{"key":"B16","volume-title":"The effects and mechanisms of paeoniflorin on murine ovarian cells for the treatment of polycystic ovarian syndrome","author":"Ong","year":"2018"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2019.11.003","article-title":"Polycystic ovarian syndrome: correlation between hyperandrogenism, insulin resistance and obesity","volume":"502","author":"Zeng","year":"2020","journal-title":"Clin Chim Acta"},{"key":"B18","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1097\/MED.0000000000000215","article-title":"Chromogranin A: any relevance in neuroendocrine tumors","volume":"23","author":"Kidd","year":"2016","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5114\/aoms.2016.57577","article-title":"Chromogranin A \u2013 unspecific neuroendocrine marker","volume":"12","author":"Gut","year":"2016","journal-title":"Arch Med Sci"},{"key":"B20","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-58338-9_8","article-title":"Cardiac physiopharmacological aspects of three chromogranin A-derived peptides: vasostatin, catestatin, and serpinin","volume-title":"Chromogranins: from cell biology to physiology and biomedicine","author":"Angelone","year":"2017"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1529-8019.2010.01369.x","article-title":"Skin manifestations of hormone-secreting tumors","volume":"23","author":"Jabbour","year":"2010","journal-title":"Dermatol Ther"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.4081\/rt.2011.e41","article-title":"Clinical utility of chromogranin A and octreotide in large cell neuroendocrine carcinoma of the uterine corpus","volume":"3","author":"Shahabi","year":"2011","journal-title":"Rare Tumors"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.4103\/0019-509X.146776","article-title":"Elevated chromogranin A serum levels in ovarian carcinoma patients","volume":"51","author":"Malaguarnera","year":"2014","journal-title":"Indian J Cancer"},{"key":"B24","article-title":"Chromogranin A serum levels in elderly patients with ovarian cancer","volume":"30","author":"Cataniab","year":"2014","journal-title":"Acta Med Cordoba"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.20168","article-title":"Elevation of CA 19\u20139 and chromogranin A, in addition to CA 125, are detectable in benign tumors in leiomyomas and endometriosis","volume":"21","author":"Tsao","year":"2007","journal-title":"J Clin Lab Anal"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1530\/EC-14-0027","article-title":"Biological function and clinical relevance of chromogranin A and derived peptides","volume":"3","author":"D\u2019amico","year":"2014","journal-title":"Endocr Connect"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2017.00020","article-title":"Chromogranin A regulation of obesity and peripheral insulin sensitivity","volume":"8","author":"Bandyopadhyay","year":"2017","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.archoralbio.2015.11.005","article-title":"Impact of glycemic control on oral health status in type 2 diabetes individuals and its association with salivary and plasma levels of chromogranin A","volume":"62","author":"Kogawa","year":"2016","journal-title":"Arch Oral Biol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.1997.1070915.x","article-title":"The counterregulatory response to hypoglycaemia in women with the polycystic ovary syndrome","volume":"46","author":"Gennarelli","year":"1997","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B30","article-title":"(CgA)\u2014the influence of various factors in vivo and in vitro, and existing disorders on its concentration in blood","volume":"62","author":"Glinicki","year":"2011","journal-title":"Endokrynol Pol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1682910\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T06:46:37Z","timestamp":1765953997000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1682910\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,17]]},"references-count":30,"alternative-id":["10.3389\/fendo.2025.1682910"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1682910","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,17]]},"article-number":"1682910"}}